UroGen Pharma Ltd.
URGN
$9.66
-$0.01-0.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.29% | 15.64% | 17.22% | 24.00% | 28.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.29% | 15.64% | 17.22% | 24.00% | 28.52% |
| Cost of Revenue | -5.13% | -6.88% | -4.24% | 5.12% | 22.30% |
| Gross Profit | 11.13% | 18.74% | 20.26% | 26.66% | 29.36% |
| SG&A Expenses | 28.71% | 22.68% | 18.24% | 11.73% | 12.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.52% | 16.58% | 11.05% | 4.36% | 3.38% |
| Operating Income | -46.00% | -17.59% | -5.13% | 12.51% | 17.09% |
| Income Before Tax | -26.16% | -6.71% | -1.93% | 8.89% | 8.98% |
| Income Tax Expenses | -27.76% | 434.70% | 167.28% | 172.43% | 123.36% |
| Earnings from Continuing Operations | -24.09% | -9.78% | -4.16% | 6.53% | 6.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.09% | -9.78% | -4.16% | 6.53% | 6.87% |
| EBIT | -46.00% | -17.59% | -5.13% | 12.51% | 17.09% |
| EBITDA | -47.30% | -18.36% | -5.64% | 12.38% | 17.13% |
| EPS Basic | 13.49% | 26.12% | 30.54% | 30.14% | 22.64% |
| Normalized Basic EPS | 13.21% | 28.18% | 31.93% | 31.52% | 23.70% |
| EPS Diluted | 13.49% | 26.12% | 30.54% | 30.14% | 22.64% |
| Normalized Diluted EPS | 13.21% | 28.18% | 31.93% | 31.52% | 23.70% |
| Average Basic Shares Outstanding | 39.19% | 46.34% | 49.69% | 36.38% | 26.28% |
| Average Diluted Shares Outstanding | 39.19% | 46.34% | 49.69% | 36.38% | 26.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |